CORE--VACCINE AND IMMUNOLOGY

核心——疫苗与免疫学

• 批准号: 6099394
• 负责人: Arye Rubenstein
• 金额: $ 5.71万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-03-01 至 2000-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6099394
• 关键词: AIDS vaccines; HIV envelope protein gp120; antiviral antibody; biomarker; biomedical facility; cellular immunity; cytotoxic T lymphocyte; enzyme linked immunosorbent assay; human immunodeficiency virus 1; humoral immunity; immunoglobulin A; immunoglobulin G; immunologic assay /test; lymphocyte proliferation

The redirection of the thematic areas at the AECOM CFAR to immune-based therapeutic and preventive agendas has mandated in 1990 the conversion of the original hybridoma core into an immunology/vaccine core. This new core standardizes a wide array of immunology markers in the context of antiviral and immune based interventions targeted at manifestation of host defense mechanisms in order to prevent infection or improve outcome. The core will provide access to otherwise unobtainable research capabilities in two major categories critical for the CFAR's progress: (a) Immunological surrogate markers, such as neopterin, Beta2, TNFalpha, sCD8. (b) HIV specific assays targeted to variety of epitopes, but currently focused on gp120 and in the V3 loop primary neutralizing domain (PND) (i) Humoral immune response: serum and secretory IgA (purified at the core) will be assessed for PND reactivity, PND high affinity/avidity cross reactivity; PND and IgG-subclass specific antibodies. (ii) Cellular immunity: Antigen (PND;gp120) driven lymphocyte proliferation, secretion of IL2;IL4;IL10; and specific CTLs of PBMC and sorted cells. This core will be highly interactive with other cores, but more so with the FACS and virology cores. The Core Director will continuously assess the needs for incorporation of new promising immunological assays critical in advancing the common goals of the CFAR and the AECOM-AIDS research agenda. He will be responsible to keep CFAR investigators abreast of new developments in core capabilities and enrich those by interaction with the CFAR committees, the EAC and through visiting scientists/consultants.

将AECOM CFAR的主题领域重定向为基于免疫的 治疗和预防议程已于1990年授权转换， 将原始杂交瘤核心转化为免疫学/疫苗核心。 这种新的核心在免疫系统中包含了广泛的免疫学标志物。 抗病毒和基于免疫的干预措施的背景， 宿主防御机制的表现，以防止感染 或改善结果。 核心将提供访问，否则 在两大类关键的研究能力， CFAR的进展： (a)免疫替代标记物，如新蝶呤、β 2、TNF α， sCD8。 (b)针对多种表位的HIV特异性测定，但目前 集中于gp 120和V3环中的主要中和结构域（PND） (i)体液免疫应答：血清和分泌型伊加（在 核心）将评估PND反应性、PND高亲和力/亲合力 交叉反应性; PND和IgG亚类特异性抗体。 (ii)细胞免疫：抗原（PND; gp 120）驱动的淋巴细胞 PBMC的增殖、IL 2、IL 4、IL 10的分泌和特异性CTL， 分选细胞。 该核心将与其他核心高度交互，但与 流式细胞仪和病毒学核心 核心主任将不断评估 需要结合新的有前途的免疫学测定 在推进CFAR和AECOM-AIDS的共同目标方面至关重要 研究议程。 他将负责保持CFAR调查员 跟上核心能力的新发展，并通过以下方式丰富这些能力： 与CFAR委员会、EAC的互动，并通过访问 科学家/顾问